Today: 9 June 2026
Celestica stock jumps as Big Tech AI capex forecasts lift suppliers

Celestica stock jumps as Big Tech AI capex forecasts lift suppliers

NEW YORK, Feb 6, 2026, 13:13 EST — Regular session trading.

Celestica Inc shares surged nearly 6% Friday, part of a wider upswing among AI hardware names as investors piled in on hopes for higher data-center outlays by big cloud players. The stock wrapped up at $312.31, gaining 5.9% and trading from $290.02 to $315.36 over the course of the day.

Timing matters here. The market’s looking at this new wave of capex—money poured into things like data centers and gear—and wondering if it’ll turn into real orders fast enough to make the spending worthwhile. Reuters says Alphabet, Microsoft, Amazon, and Meta together are set to sink more than $630 billion into AI this year. “Investors right now are not forgiving about large investments without clear signal on return on invested capital,” Morgan Stanley analysts noted. Investing.com Canada

U.S. stocks steadied on Friday after a rough, tech-led rout. Chip and hardware names led the bounce. Some of the biggest companies, though, lost ground as investors fretted over spending outlooks. Amazon’s projection of sharply higher capital spending in 2026 put pressure on parts of the “Magnificent Seven” pack, according to Reuters. Reuters

Alphabet’s latest spending binge has investors poring over possible supply chain knock-ons. Celestica got a nod from Investors.com as a company poised to benefit from Google’s heavier AI data-center outlays. Jefferies’ Blayne Curtis, for his part, didn’t budge on Broadcom—he’s still calling it a “top pick” and left his $500 price target untouched. Investors

Celestica has been stepping up efforts in this space. In its January earnings release, the company rolled out plans to expand U.S. manufacturing capacity to support production of Google’s Tensor Processing Unit (TPU) systems, positioning itself as Google’s go-to partner for data center hardware builds. Alongside that, Celestica raised its 2026 revenue forecast to $17.0 billion and bumped its adjusted earnings per share target to $8.75—a non-GAAP figure that leaves out certain items. CEO Rob Mionis noted the company is “strategically increasing” its planned capital expenditure to $1 billion this year, aiming to cover the funding with cash generated from operations. SEC

Celestica wasn’t the only mover. Jabil shares popped nearly 7.0%. Flex tacked on about 8.1%. Sanmina picked up 5.6%. Broadcom, for its part, advanced close to 7.5% over the session.

This week’s filing shows institutions aren’t backing off. Fidelity’s FMR LLC now reports a 6.4% stake in Celestica, according to a Schedule 13G/A sent to the U.S. Securities and Exchange Commission.

Still, the bright side comes with hazards. Should hyperscalers, those big cloud firms, scale back orders, stall their rollouts, or start leaning on suppliers for price cuts, all that increased spending from Celestica could quickly turn from fueling growth to weighing the company down.

Nvidia’s quarterly numbers, due Feb. 25, will give investors another read on the trade. The company’s update often acts as a proxy for measuring AI infrastructure demand up and down the supply chain.

Stock Market Today

  • Aker BP Share Price Surges Amid Valuation Debate
    June 9, 2026, 11:54 AM EDT. Aker BP (OB:AKRBP) shares climbed to NOK347.7, marking a 55.05% total shareholder return over one year, outperforming peers in Norway's energy sector. Despite this momentum, the stock trades at an 8.6% premium over a fair value of NOK320.11, raising questions about valuation. The company aims to sustain production above 500,000 barrels per day past 2030, backed by projects like Yggdrasil and Johan Sverdrup, supporting revenue growth. Yet, potential risks include higher emissions costs and delays in key developments. Analysts offer cautious pricing, but a discounted cash flow (DCF) model from Simply Wall St suggests a much higher intrinsic value of NOK1,769.75, indicating significant undervaluation. Investors face a valuation divide between conservative targets and optimistic cash flow projections.

Latest articles

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Coupang Stock Gains as Privacy Ruling Approaches

Coupang Stock Gains as Privacy Ruling Approaches

9 June 2026
Coupang shares jumped 2% to $15.49, outperforming a falling market, as investors braced for South Korea’s privacy regulator to decide June 10 on possible sanctions over a data breach exposing 33.6 million records—a ruling that could trigger fines up to 3% of sales and impact the stock’s recovery.
AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

9 June 2026
AEP lifted its five-year capital plan to $78 billion after signing 7 gigawatts of new large-energy project agreements, with 90% of 63 gigawatts of expected incremental load by 2030 tied to data centers; shares recently traded at $127.27, up 26.9% over 52 weeks, with analysts’ mean price target at $142.76, as investors weigh execution risks and a new data-center rate structure.
Dow climbs in New York, but gains may stall

Dow climbs in New York, but gains may stall

9 June 2026
Dow jumps 154.87 points as tech rebounds and oil prices drop, with chipmakers like Intel and Broadcom up sharply; investors brace for Wednesday’s key inflation data and next week’s Fed meeting, which could sway rate expectations and market direction.
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

9 June 2026
Nuvalent soared after GSK agreed to buy the cancer drug developer for $10.6 billion in cash, valuing shares at $124—a 40% premium to Monday’s close—while investors awaited Wednesday’s key inflation data that could impact market direction and tech stock stability.
AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt
Previous Story

AbbVie stock rises as investors re-rank Rinvoq and Skyrizi after earnings jolt

AI stocks swing hard: Nvidia jumps as Amazon slides on $200 billion AI spend
Next Story

AI stocks swing hard: Nvidia jumps as Amazon slides on $200 billion AI spend

Go toTop